why choose us

First received: January 05, 2023

Clinical Trial: US Selumetinib Registry

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neurofibromatosis Type 1

Study Type: OBSERVATIONAL


Official Title: US Selumetinib Registry

Brief Summary: The purpose of this study is to understand treatment patterns and assess long-term effectiveness and safety outcomes associated with selumetinib treatment as well as to explore clinical and non-clinical factors affecting those outcomes in participants with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs) who were aged 2 to 18 years at the time selumetinib was started in a real-world setting.

Read more